Mammalian tumor and stromal cells

Mammalian tumor and stromal cells refer to the complex, heterogeneous cellular ecosystem known as the tumor microenvironment (TME). This entity encompasses both the malignant neoplastic cells and the surrounding non-malignant components, including fibroblasts, immune cells, endothelial cells, and the extracellular matrix (Hanahan & Weinberg, 2011). The stroma is not merely a passive scaffold but an active participant in cancer progression, providing essential growth factors, promoting angiogenesis, and facilitating immune evasion (Quail & Joyce, 2013). Because this term describes a broad biological context rather than a single protein or pathway, it is not considered a specific molecular target in the traditional pharmacological sense. Instead, drug development focuses on specific receptors or enzymes within these cells, such as PD-1 on T-cells or VEGF in the vascular stroma, to disrupt the supportive niche that allows tumors to thrive and resist treatment (Balkwill et al., 2012). Understanding the dynamic interplay between tumor and stromal cells is critical for the design of combination therapies that address the multifaceted nature of solid tumors (Joyce & Pollard, 2009).

Other names

Tumor microenvironmentTMECancer-associated stromaTumor-stroma interactionNeoplastic and stromal compartments

Therapeutic strategies targeting this system involve disrupting the crosstalk between malignant cells and their supporting environment, including inhibition of angiogenesis, modulation of immune checkpoints, and depletion of cancer-associated fibroblasts.